Navigation Links
AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
Date:2/3/2009

New York, Feb. 3 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) is a New York-based biotechnology company that is pioneering the targeting of Id genes and proteins for the discovery and development of anti-angiogenic drugs to treat cancer. Today the Company announced that it presented animal data at two recent scientific meetings that demonstrate the ability of its lead small molecule candidate drug AGX51 to mitigate tumor formation and metastases.

Dr. Robert Benezra, the scientific founder of AngioGenex and Head of the Company's Scientific Advisory Board presented at the Keystone Symposium held January 1-6 in Big Sky, Montana on Angiogenesis and Lymphangiogenesis in Cancer, and Dr. William Garland, the Company's CEO, presented at the PepTalk meeting held January 11-16 in San Diego, California.

Besides AGX51, both speakers also touted the continually emerging importance of Id in the development and progression of cancer and the therapeutic potential of the novel, anti-Id oligonucleotides invented by Dr. Benezra. An initial report on one of these oligonucleotides (AGX1053) appeared last year in Nature Biotechnology 2008; 26: 91-100.

AngioGenex is currently pursuing the preclinical development of its small, patented molecules and oligonucleotides that have potent anti-angiogenic / anti-tumor activity through inhibition of the action of the Id proteins. The Chairman of the Board of AngioGenex, Dr. Richard Salvador, commented that "information accruing on the control of new blood vessel formation into tumors by the Id genes and proteins confirms that drugs that inhibit their activity, such as AGX1053 and AGX51, are the first in a class of new and unique anti-tumor agents. With sufficient funding we plan to have both drugs in man in 9 to 12 months. Our technology offers a potentially more effective and, therefore, a more cost effective anti-angiogenic based therapy for cancer tha
'/>"/>

SOURCE AngioGenex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. William Garland Joins AngioGenexs New Board of Directors
2. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
3. AngioGenex Reviews 2008 Achievements and Sets Goals for 2009
4. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
5. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Presents Preclinical Data on AR-2474 at ICAAC
11. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 31, 2015 CytoSorbents Corporation (NASDAQ CM: ... purification to treat critically-ill and cardiac surgery patients ... and reports financial results for the fiscal year ... CytoSorb® product revenues were a record $3.1M, an ... CytoSorb® revenues of $0.8M Highlights for the Year ...
(Date:3/31/2015)... 31, 2015  Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... Conway, Arkansas . The over 16,000 square foot ... March 26 th 2015 and brings the total ... "This facility represents another milestone in our ...
(Date:3/31/2015)... VANCOUVER , March 31, 2015  /PRNewswire/ - ESSA Pharma ... that it has filed with the Food and Drug ... ("IND") application related to the Company,s proposed clinical trial ... IND application is required in order for ESSA to ... The IND application is a complete description ...
(Date:3/31/2015)... March 31, 2015 Eastern Kentucky ... for online bachelor’s of criminal justice degree programs ... people to inspiring ideas and high quality educational ... to the University. We are confident that students ... , This is the site’s first “Students before ...
Breaking Biology Technology:CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... year-end financial results on Monday, Mar. 3,2008. SuperGen ... and provide financial guidance for fiscal year-end 2008., ...
... Assist Local Efforts To Improve Diabetes Care, ... program to improve the medical, humanistic and financial ... National Business Coalition on,Health (NBCH). FrontPath Health Coalition, ... of Perrysburg, Ohio, will lead this,community-wide effort that ...
... Symmetry Medical Inc.,(NYSE: SMA ), an independent ... other medical markets, announced today that Brian S.,Moore, President ... Canaccord Adams Small-Cap Orthopedics Conference at The Mission Bay,Conference ... March 4, 2008,at 1:50 p.m. PT (4:50 p.m. ET)., ...
Cached Biology Technology:SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008 2FrontPath Health Coalition To Lead Community-wide Group in Pilot Program 2FrontPath Health Coalition To Lead Community-wide Group in Pilot Program 3Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference 2
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... invasion biology faces a new challenge as 19 eminent ... non-native species" in the journal Nature . ... that non-native species could just as easily be coined ... The authors of the Nature comments section note that ...
... . , They can cause lung cancer and other ... of diesel-engined vehicles. The quantity of these particles has increased ... one,s physical health due to soot particles low, the limit ... step, from 180 mg/km (EURO 1, 1993) down to 5 ...
... hitting a note that shatters a glass, a signal ... a material and change its properties. And as with ... change the critical pitch. Echoing both phenomena, researchers at ... demonstrated a unique fluid-tuned "metasurface," a concept that may ...
Cached Biology News:Ecology biased against non-native species? 2Pan-European research project for clean air 2Pan-European research project for clean air 3NIST tunes 'metasurface' with fluid in new concept for sensing and chemistry 2
... the legendary MSn performance of the LTQ, ... through Thermo Scientifics innovations in ion trap ... the only mass spectrometer that offers multiple ... Pulsed Q Collision Induced Dissociation (PQD) is ...
... Varian, Inc.'s CP-4900 is ... that always delivers the information ... site. When the composition of ... 4th generation micro-Gas Chromatograph generates ...
... Peroxisome Proliferator-Activated Receptor-gamma (PPARGamma) Competitor ... and efficient method for studying ... using fluorescence polarization (FP). The ... domain (PPARGamma-LBD) with an N-terminal ...
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
Biology Products: